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The field of intracoronary imaging emerged to overcome the drawbacks of coronary angiography. The visual evaluation of lesion severity of coronary stenosis by angiography remains insufficient for accurate diagnosis of the vessel indices and its estimate of functional significance. 1 Intracoronary imaging was introduced to optimize the outcome of percutaneous coronary intervention (PCI), aiming to reduce short-and long-term cardiovascular events. Intracoronary imaging systems, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), offer an inside look into the artery, which enables precision in evaluation of the vessel dimension, plaque composition, and degree of narrowing, and allows optimization of management by selecting the appropriate method of intervention, such as pre-dilatation with balloon vs. direct stenting, use of atheroablative devices, 2 stent sizing, and optimization of stent deployment and lesion coverage. IVUS-guided PCI has been in use for over two decades and has demonstrated a major contribution in regard to the importance of stent expansion and apposition that resulted in reduction of stent thrombosis. Overall, numerous studies showed that intracoronary imaging is safe and feasible for guidance of coronary interventions. 3, 4 However, the lack of adequately powered randomized clinical trials to support improvement in outcome, difficulties in image interpretation, and cost limited its utilization to guide routine PCI. Nevertheless, a few meta-analyses suggest that IVUS-guided stent placement could improve clinical outcome 5 by reducing stent thrombosis, restenosis, and repeat revascularization. 6 Other indications such as assessment of intermediate lesions by IVUS showed only modest correlation to fractional flow reserve (FFR). 7 Although intracoronary imaging to detect plaque morphology may impact the physician decisionmaking process, it has not proven to improve clinical outcomes. 8, 9 In the last decade, the focus has shifted to physiological assessment of intermediate lesions using FFR, which has proven to be effective in deciding whether intermediate lesions should be treated by PCI or deferred in three randomized clinical trials. 10 -13 The professional societies differentiated the guidelines' class level for the physiological (FFR) and anatomical (invasive imaging IVUS) assessments. FFR has a higher class level than IVUS for the evaluation of intermediate coronary lesions with a class of recommendation IIa, level of evidence A in the American guidelines and recommendation Ia, level of evidence A in the European guidelines. FFR-guided multivessel PCI has a similar indication to IVUS, recommendation II(a), level of evidence B. For IVUS, the American College of Cardiology Foundation/American Heart Association/Society for Cardiac Angiography and Interventions PCI guidelines from 2011 14 gave a class IIa, level of evidence B for the diagnostic assessment with IVUS in the case of: (i) angiographically indeterminante left main coronary artery disease (LMCAD); (ii) progressive allograft vasculopathy after transplantation; and (iii) in-stent restenosis. However, in the case of stent thrombosis, the class of recommendation with IVUS is class IIb (level of evidence C). Moreover, routine lesion assessment is not recommended when revascularization with PCI or coronary artery bypass grafting is not being contemplated (level of evidence C). Concerning the European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization from 2014, 15 the use of IVUS is class IIa: (i) in selected patients to optimize stent implantation (level of evidence B); (ii) for assessment of lesion severity and optimization of treatment of unprotected left main lesions (level of evidence B); and (iii) to assess mechanisms of stent failure (level of evidence C).
Optical coherence tomography entered the stage as an upgrade of intracoronary imaging, providing a resolution that is greater than IVUS: 10 -15 mm axial resolution and 20 -25 mm lateral and out-of-plane resolutions, with faster acquisition of seconds vs. minutes by IVUS. Although the image is spectacular, and the ease of use and interpretation has been improved, the appropriate role of OCT in routine clinical decision-making has not been established because
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. † doi:10.1093/eurheartj/ehv367. of lack of clinical data to support the clinical utility of the device for routine OCT-guided PCI. The role of OCT according to the guidelines remains limited. The US guidelines do not include OCT, and in the European guidelines, OCT has only a class IIb recommendation, level of evidence C for stent optimization. Whether the guidelines of IVUS can be generalized to OCT should be subjected to clinical trials. ILUMIEN III will compare these two modalities, and, if equivalence is shown, it may grant OCT similar guidelines to IVUS. Currently, the use of intracoronary imaging-guided PCI remains low: the rate of use of IVUS in the USA is ,20%, 16 and its rate in Europe is estimated at 10%. The estimated adoption rate for OCT is 1% in the USA and 3% in Europe. This low adoption of OCT may also be the reason for low reimbursement and the lack of labelling. ILUMIEN I is the largest study to date attempting to define guidance parameters for stent optimization utilizing OCT. 17 The study focuses primarily on the impact of OCT findings pre-and post-PCI on physician decision-making and the association with post-PCI FFR values and early clinical events. Physician decision-making was indeed affected by the OCT imaging prior to PCI in 57% and post-PCI in 27% of all cases, using additional in-stent post-dilatation (81%, 101/124) or placement of 20 new stents (12%).
The investigators should be congratulated for the lower event rate in their study. This may be credited to their careful assessment of the anatomy and attempt to optimize the PCI in all groups, including angio alone. However, this low event rate was similar across all the study groups, and it was beyond the capacity of the study to detect clinical differences. The corrective measure for the most part was not evidence based, except for adequate stent expansion; for example, it is not clear that non-limiting edge dissections required further intervention or additional stents. In addition, OCT-guided imaging resulted in longer procedures, more stent utilization, and obviously increased cost. Without proven clinical benefit especially for hard endpoints, such as death, myocardial infarction, and target lesion revascularization, it would be hard to justify routine use of OCT as a tool to guide PCI. Furthermore, although the main finding of the study was the impact of imaging on decision-making, without corrective management direction, one cannot tell whether the corrective management was based exclusively on OCT or due to other considerations, such as a second evaluation of the angiogram. Finally, it is not clear that the change was a good one and contributed to improvement in clinical outcome. As a matter of fact, over-reaction to imaging findings, such as stenting edge dissection, without limiting flow can be harmful and potentially increases the incidence of late restenosis or stent thrombosis.
Although there is a consensus on the lack of accuracy of vessel sizing by angio and by quantitative coronary arteriography that tends to undersize the actual vessel size, IVUS on the contrary may lead to overestimation of the size, and the same may apply to OCT as very little is known about how OCT should be used to select optimal stent size, and there are no validation data to compare OCT with IVUS.
ILUMIEN 1 is missing a control arm of patients who did not undergo imaging evaluation or underwent only documentary imaging to evaluate whether OCT guidance for optimization of stent implantation indeed impacted clinical outcomes. Further, the ILU-MIEN I study does not tell us the appropriate thresholds for corrective measures. The study also does not tell us how pre-PCI OCT findings of plaque morphology guide the physician to select a device or a strategy to treat the lesion, such as pre-dilatation or direct stenting, or whether the morphology could predict an event such as distal embolization. Finally, the manuscript is missing the health economics aspect of OCT-guided PCI. All these factors should be the subject of future investigation-preferably prospective clinical randomized studies. One of the challenges in designing such studies is a proper selection of patients and lesions. It is hard to imagine that intracoronary imaging is useful for every PCI and by every operator. The utility of intracoronary imaging to optimize clinical outcome may vary for different subsets of patients and lesions. Some are definitely beneficial, for example, for the treatment of left main disease 18 or in-stent restenosis, and some are only possibly beneficial, for example, for the assessment of the degree of severity of the lesion or for the treatment of ST-segment elevation myocardial infarction. Based on our clinical practice, the practice of others, and published data, we propose three category levels ( Table 1) . These can be subjected to further update as more data are gathered. There is no doubt that intracoronary imaging is useful and has a major role to assess new technology. We learned that with the introduction of bare metallic stents, drug-eluting stents, and now biodegradable scaffolds, intracoronary imaging helped to optimize the implantation of these devices. Once the technology and the intervention strategy matured, the role of intracoronary guidance imaging was somewhat diminished. While OCT technology allows us to see more than IVUS, the question remains: is seeing more better or worse? ILU-MIEN III will evaluate OCT vs. IVUS, but the future of intracoronary In-stent restenosis: determination of mechanism * Evaluation of lesion severity: non-LMCAD imaging will be dependent on demonstrating clinical utility with improvement of clinical hard endpoints and health economics when compared with angio alone. Only then will we be able to support routine use of this advanced imaging technology. Conflict of interest: R.W. reports personal fees from Biotronik, Medtronic, and Abbott Vascular, grants and personal fees from As-traZeneca and Boston Scientific, and grants from The Medicines Company and Edwards Lifesciences, outside the submitted work. R.D. has no conflicts to declare.
